Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Investments Regulatory News (BRH)

  • There is currently no data for BRH

Commercialisation Agreement

23 Jun 2008 07:01

RNS Number : 2343X
Braveheart Investment Group plc
23 June 2008
 



For release:07.00, 23 June 2008

Braveheart Investment Group plc

("Braveheart" or the "Group")

BRAVEHEART SIGNS COMMERCIALISATION AGREEMENT WITH UNIVERSITY OF ABERDEEN

Braveheart strengthens its University ties by signing deal with the University of Aberdeen to commercialise intellectual property for up to 15 years ("the University")

Braveheart (AIM: BRH), the technology commercialisation and investment management company, announces

that it has signed an agreement with the University of Aberdeen under which the two parties shall work

together to grow further the commercialisation of technology and intellectual property ("IP") emanating from the

University.

The University of Aberdeen was founded in 1495 making it the third oldest University in Scotland and the fifth oldest in the UK. It educates close to 14,000 students and has attracted research awards of up to £50 million to date. The University has particularly strong commercialisation expertise in the areas of life science, medicine, engineering and geosciences. The University has been awarded 22 Proof of Concept awards and a further seven awards from the Nestech Fund to date, and its Research and Innovation department has been involved in a number of spin-outs including Brinker Technology, Haptogen and B1 Medical. 

Under the terms of the agreement Braveheart will provide funding to finance spin-outs and will have the

mechanism to fund projects leading to licensing deals arising from University IP, as well as sponsoring the

University's annual "Blue Skies" business plan competition. In return, the University will grant Braveheart

a time limited exclusive right of first refusal in respect of all those commercial investment

opportunities in relevant defined areas.

The agreement constitutes a 'two phased' approach; Phase one will involve the two parties working together

to further stimulate and increase the commercialisation of IP within the University. Braveheart will provide

support in both financial and resource terms; funding will be made available via its existing Alpha EIS Fund, as

well as private client monies. The total funding package is anticipated to be around £5 million. It will also use

its network of experienced investors to provide crucial mentoring support to investee companies on

corporate development issues.

Phase two of the agreement will involve Braveheart setting up and managing a dedicated fund or resource for

the future commercialisation of University technology with funds being provided from Braveheartthe

University and other sources.

It is anticipated that Phase one will last between two and five years, depending on the results achieved, whilst

Phase two would have an initial investment period of five years with a subsequent follow-on investment and

management period of five years, giving the agreement a total lifespan of 15 years. 

Commenting on the investment, Geoffrey Thomson, Chief Executive of Braveheart said, "Our close

relationships with universities form the cornerstone of our strategy of identifying the most exciting early stage

technologies for our investors. We are delighted to have signed our third university partnership agreement and are confident that Aberdeen will remain a stronghold of research and development over the course of our

partnership." 

Professor Dominic HoulihanVice-Principal for Research and Commercialisation of

the University of Aberdeen added: "The University has a strong track record of high quality

research and the translation of that research into commercialisation opportunities. In Braveheart we believe we

now have a partner with proven ability to help us to strengthen our commercialisation success and we look

forward to working with them.

For further information please visit www.braveheart-ventures.co.uk or contact:

Braveheart Investment Group

Tavistock Communications (for Braveheart)

Geoffrey Thomson, Chief Executive

Clemmie Carr / James Midmer

Tel: 01738 587555

Tel: 020 7920 3150

gthomson@braveheart-ventures.co.uk

carr@tavistock.co.uk 

The University of Aberdeen

Jennifer Phillips

Tel: 01224 273 174

j.phillips@abdn.ac.uk

Notes to Editors

Braveheart

 

Braveheart Investment Group is a technology commercialisation and investment management company based in PerthScotland. Since its formation in 1997 it has made the transition from start-up angel syndicate to fully listed company. Braveheart's shares listed on AIM in March 2007.

Investments are made in young, emerging, unlisted companies where there is potential for significant growth through successful commercialisation of IP and Braveheart enjoys close relationships with several universities to identify emerging technologies. Investments are predominantly technology-focused; however the Group also maintains limited exposure to more traditional businesses.

Braveheart's diverse portfolio currently comprises over 30 companies and it has completed over 70 deals in its ten year history, including 6 IPOs, 3 trade sales and 8 write-offs and has an exit IRR of 37%.

At the 2008 Ernst & Young Entrepreneur of The Year Awards (Scotland) Braveheart CEO Geoffrey Thomson was given a special award recognising his contribution and support of emerging technology businesses in Scotland over the past decade.

The Alpha EIS Fund ("the Fund")

Established in December 2005, the £2.5 million Fund was set up as a tax efficient vehicle to invest in early-stage, university spin out companies, rich in intellectual property, with potential for significant growth, through the commercialisation of their IP. The Fund is managed by Braveheart and participants and co-investors include Bank of Scotland Corporate, Scottish Enterprise's Co-investment Fund and Braveheart's own clients. The Fund will deliver a minimum of ten EIS qualifying investments, sourced through the Group's unique framework of strong formal relationships with Scottish universities and business parks.

To date the Fund has made 8 investments from the Alpha Fund, totalling in excess of £1 million.

 

The University of Aberdeen

Many of the University's portfolio of over 90 patents are currently being exploited by industry through 54 license agreements and 12 spin-outs; the latter having raised investment of £48.5M. Three of those spin-outs were sold or partially sold in the last year.

 

The University of Aberdeen is an acknowledged centre of excellence for Life Sciences 

and Medicine. Translational research is one area of particular strength because of its wide range of internationally recognised health research, underpinned by many of its leading scientists and clinicians based on one of the largest teaching hospital sites in Europe. 

Over the last five years, the University has made major strategic investments in its estates, its people, and its infrastructure, to consolidate its position as one of the world's key centres for R&D in life sciences, medical research, and physical sciences.

With its ambitious Sixth Century Fundraising Campaign, the University is one of the most progressive fundraising higher education institutions in the UK. Over the last two years, Aberdeen has recruited more than 50 senior academic leaders from institutions all over the world. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKGGZVKGMGRZM
Date   Source Headline
10th Oct 20251:20 pmRNSConfirmation of change of name and website
26th Sep 20257:00 amRNSProposed Change of Name
9th Sep 20257:00 amRNSBlock admission six monthly return
2nd Sep 202511:23 amRNSHolding(s) in Company
1st Aug 20253:04 pmRNSResult of AGM
9th Jul 20252:41 pmRNSFinal Results and Notice of AGM
30th May 20255:00 pmRNSTotal Voting Rights
27th May 20253:15 pmRNSHolding(s) in Company
21st May 20257:00 amRNSResult of Broker Option and Total Voting Rights
16th May 20252:08 pmRNSPlacing to raise £135,000
14th May 202511:55 amRNSHolding(s) in Company
18th Mar 202510:30 amRNSSubscription in IQ-AI Ltd Placing
6th Mar 202510:03 amRNSBlock admission six monthly return
3rd Feb 20257:00 amRNSCancellation of options
20th Jan 20255:32 pmRNSDirector/PDMR Shareholding - acquisition of shares
14th Jan 202511:15 amRNSHolding(s) in Company
8th Jan 20254:54 pmRNSChange of Auditor
10th Dec 20241:28 pmRNSDirector/PDMR Shareholding
9th Dec 202412:16 pmRNSDirector/PDMR Shareholding - acquisition of shares
2nd Dec 20244:22 pmRNSHolding(s) in Company
2nd Dec 20249:05 amRNSDirector/PDMR Shareholding
7th Nov 202411:10 amRNSHolding(s) in Company
7th Nov 202411:06 amRNSDirector/PDMR Shareholding - acquisition of shares
15th Oct 202410:28 amRNSHolding(s) in Company
15th Oct 20247:00 amRNSHalf-year Report
11th Oct 202410:00 amRNSInvestment in IQ-AI Limited and RPT
26th Sep 20249:35 amRNSAppointment of representative to Board of Autins
9th Sep 202410:15 amRNSBlock admission six monthly return
4th Sep 20247:00 amRNSHolding(s) in Company
20th Aug 20245:15 pmRNSHolding(s) in Company
7th Aug 20247:00 amRNSHolding(s) in Company
7th Aug 20247:00 amRNSAcquisition of interest in Image Scan Holdings plc
6th Aug 20245:30 pmRNSHolding(s) in Company
1st Aug 20247:00 amRNSInvestment update – Gyrometric
24th Jul 20247:00 amRNSInvestment update - Kirkstall and Paraytec
24th Jul 20247:00 amRNSHolding(s) in Company
18th Jul 20242:23 pmRNSResult of AGM
15th Jul 20244:27 pmRNSGrant of options
26th Jun 20242:03 pmRNSAcquisition of further interest in Autins Group
21st Jun 20247:00 amRNSFinal Results and Notice of AGM
15th May 202411:22 amRNSRevaluation of portfolio assets
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.